TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SW14525

Delayed Deutsche Boerse AG 20:41:19 28/05/2024 BST
10 EUR +2.15% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - BIOMARIN PHARMACEUTICAL
1 month+3.27%
3 months+15.86%
Date Price Change
28/05/24 10 +2.15%
27/05/24 9.79 -0.91%
24/05/24 9.88 -0.30%
23/05/24 9.91 +1.12%
22/05/24 9.8 +0.72%

Delayed Quote Deutsche Boerse AG

Last update May 28, 2024 at 08:41 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SW1452
ISINDE000SW14525
Date issued 10/08/2023
Strike 181.9 $
Maturity Unlimited
Parity 10 : 1
Emission price 8.3
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 10
Lowest since issue 7.56
Spread 0.01
Spread %0.10%

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.52 USD
Average target price
109.3 USD
Spread / Average Target
+44.76%
Consensus